Quantitative Mid-Infrared Plasmonic Biosensing on Scalable Graphene Nanostructures

Nestor Jr Bareza, Ewelina Wajs*, Bruno Paulillo*, Antti Tullila, Hannakaisa Jaatinen, Roberto Milani, Camilla Dore, Agustin Mihi, Tarja K. Nevanen, Valerio Pruneri

*Corresponding author for this work

Research output: Contribution to journalArticleScientificpeer-review

8 Citations (Scopus)

Abstract

Graphene nanostructures, exhibiting tunable and nanoscale-confined mid-infrared (mid-IR) plasmons, prevail as a powerful spectroscopic platform for novel surface-enhanced molecular identification. Particularly, graphene shows exciting opportunities for biosensing applications due to its versatile functionalization methods with different biomolecular building blocks (e.g., enzymes, proteins, and DNA). Here, a quantitative bioassay based on the mid-IR localized surface plasmon resonance (LSPR) modulation in functionalized graphene nanostructures is demonstrated. Specifically, vitamin B12 (vB12) using the specific recognition elements on modified graphene nanoribbons (i.e., pyrene linkers via π − π stacking + anti-vB12 antibody fragments via amide bond) is detected. Different concentrations of vB12 spotted on an arrayed panel of a single chip are quantified by the graphene LSPR shifts, where a limit of detection (LOD) of 53.5 ng mL−1 is obtained. The upscaling potential of the bioassay using large area nanostructured graphene films produced by nanoimprinting 2D hole arrays is illustrated. The integration of quantitative bioassay with scalable graphene nanostructures shows promising routes of graphene-based mid-IR platforms toward prospective industrial applications.

Original languageEnglish
Article number2201699
Number of pages7
JournalAdvanced Materials Interfaces
Volume10
Issue number2
DOIs
Publication statusPublished - 17 Jan 2023
MoE publication typeA1 Journal article-refereed

Funding

N.B. and E.W. contributed equally to this work. Tuula Kuurila and Salla Pentikäinen from VTT were thanked for technical assistance in antibody production and purification. Harri Siitari was thanked for support as a project manager during the anti-vB12 antibody development. The authors thank Daniel Martinez for help with AFM measurements. The research leading to these results has received funding from the H2020 Programme under Grant Agreement No. 881603 (Graphene Flagship). This project has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie Grant Agreement No. 754510. This project has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie Grant Agreement No. 665884. The authors acknowledge financial support from the Spanish Ministry of Economy and Competitiveness through the ‘Severo Ochoa’ Programme for Centres of Excellence in R&D (CEX2019-000910-S and CEX2019-000917-S) and project TUNA-SURF (PID2019-106892RB-I00) and PID2019-106860GB-I00 (HIGHN), Fundació Mir-Puig, and from Generalitat de Catalunya through the CERCA program, from AGAUR 2017 SGR 1634 and the Beatriu de Pinos-3 Postdoctoral Programme (BP3) under grant agreement ID 801370. This work was partially funded by CEX2019-000910-S [MCIN/ AEI/10.13039/501100011033], Fundació Cellex, Fundació Mir-Puig, and Generalitat de Catalunya through CERCA. Antibody discovery was funded by VTT Technical Research Centre of Finland and Development6 -project funded by Turku Science Park Oy, City of Turku, Turku Bio Valley Ltd. N.B. and E.W. contributed equally to this work. Tuula Kuurila and Salla Pentikäinen from VTT were thanked for technical assistance in antibody production and purification. Harri Siitari was thanked for support as a project manager during the anti‐vB antibody development. The authors thank Daniel Martinez for help with AFM measurements. The research leading to these results has received funding from the H2020 Programme under Grant Agreement No. 881603 (Graphene Flagship). This project has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska‐Curie Grant Agreement No. 754510. This project has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska‐Curie Grant Agreement No. 665884. The authors acknowledge financial support from the Spanish Ministry of Economy and Competitiveness through the ‘Severo Ochoa’ Programme for Centres of Excellence in R&D (CEX2019‐000910‐S and CEX2019‐000917‐S) and project TUNA‐SURF (PID2019‐106892RB‐I00) and PID2019‐106860GB‐I00 (HIGHN), Fundació Mir‐Puig, and from Generalitat de Catalunya through the CERCA program, from AGAUR 2017 SGR 1634 and the Beatriu de Pinos‐3 Postdoctoral Programme (BP3) under grant agreement ID 801370. This work was partially funded by CEX2019‐000910‐S [MCIN/ AEI/10.13039/501100011033], Fundació Cellex, Fundació Mir‐Puig, and Generalitat de Catalunya through CERCA. Antibody discovery was funded by VTT Technical Research Centre of Finland and Development6 ‐project funded by Turku Science Park Oy, City of Turku, Turku Bio Valley Ltd. 12

Keywords

  • antibody
  • graphene plasmonics
  • graphene sensor
  • mid-infrared biosensor
  • SEIRA
  • vitamin B

Fingerprint

Dive into the research topics of 'Quantitative Mid-Infrared Plasmonic Biosensing on Scalable Graphene Nanostructures'. Together they form a unique fingerprint.

Cite this